Business
Agenus Announces Investor Day on February 20, 2020
LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to
About this update from Agenus Inc.
[{"type":"text","content":"LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020. \n\n \n \n\n \nThe Investor Day will present:\nClinical data from pre-planned interim analyses of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4); Clinical data from a dose-escalation study of AGEN1181, a novel multi-functional T cell engager.Date: \nThursday, February 20, 2020\nTime: \n9:00 – 11:00AM\nLocation: \nNew York, NY (by invitation only)\nEvent details: agenusbio.com\nPresenters will include global experts in immune-oncology, Dr. Chuck Drake, Co-Director, Cancer Immunotherapy Program, Columbia University Herbert Irving Comprehensive Cancer Center, and Dr. Bradley Monk, M.D., FACS, FACOG, Co‐Director of GOG Partners, Arizona Oncology (US Oncology Network) and Professor, Gynecologic Oncology at University of Arizona, and Creighton University, Medical Director of US Oncology Research Gynecology program in Phoenix, Arizona.\nThe event will be webcast live an may be accessed by visiting the \"Events & Presentations\" page within the Investors section of the Agenus website at www.agenusbio.com or by using the link below. A replay of the webcast, as well as a copy of the slide presentations that will be presented at the event, will be available on the Agenus website following the event.\nPlease note that in-person attendance is by invitation only and advanced registration is required. If you are interested in attending or for more information, please contact Regina Grebla, Agenus Investor Relations, at [email protected]. \nAbout AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clin...